U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053358) titled 'Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients' on June 27.
Brief Summary: The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subiects aged >= 50 vears old to receive a single unilateral intravitreal (lVT) iniection of LX111 to evaluate its safety and efficacy.
Study Start Date: July 02
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-related Macular Degeneration
Intervention:
GENETIC: LX111 Injection
Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.
Recruitment Status: RECRUITING
Sponsor: Sha...